|
Related results
Creatine Risks
Creatine Risks
Creatine Risks
Creatine Risks
Creatine Risks
Creatine Risks
Creatine Risks
Creatine Risks
|
FDA Approves New Labeling for ISENTRESS® (raltegravir) to Include 156-Week Data Demonstrating Long-Term Efficacy ...
Merck , known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration approved a labeling update for ISENTRESS® Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in previously untreated adult HIV-1-infected patients.
finance.yahoo.com
MusclePharm Sees Expanded Opportunity In Light Of FDA's Ban On Ingredient DMAA
DENVER, May 3, 2012 /PRNewswire/ -- MusclePharm Corporation (MSLP.OB), a nutritional supplement company focusing on all categories of an active lifestyle, today said that, in light of yesterday's FDA ...
ca.finance.yahoo.com
Press Release
Merck (NYSE: MRK), known as MSD outside the United States and Canada, today announced the U.S. Food and Drug Administration (FDA) approved a labeling update for ISENTRESS® (raltegravir) Film-coated Tablets to include 156-week data from the STARTMRK study with ISENTRESS in combination therapy compared to efavirenz in combination therapy in previously untreated (treatment-naïve) adult HIV-1 ...
www.pharmiweb.com
Dainippon Sumitomo Pharma Reports that Latuda® (lurasidone HCl) Met Primary and Key Secondary Endpoints in Two Phase ...
Dainippon Sumitomo Pharma Co., Ltd. announced today results from two Phase 3 clinical trials designed to evaluate the efficacy and safety of LATUDA as adjunctive therapy and monotherapy, respectively, in patients with bipolar I depression .
finance.yahoo.com
Increasing Incidence of Cardiovascular Diseases to Drive Cardiovascular Disease Diagnostics Market, According to a New ...
GIA announces the release of a comprehensive global report on Cardiovascular Disease Diagnostics markets. The global market for cardiovascular disease diagnostics is forecast to reach US$14.5 billion by the year 2017, primarily driven by increasing incidence of cardiovascular diseases, costs associated with the disease management, and technological advancements coupled with the increasing ...
news.yahoo.com
|
Sponsored links:
|
